Reviewing the utility of EUS FNA to advance precision medicine in pancreatic cancer

William Berry, Joanne Lundy, Daniel Croagh, Brendan J. Jenkins

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)

Abstract

Advanced pancreatic cancer (PC) is an aggressive malignancy with few effective therapeutic options. While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present no targeted therapies are used in the routine management of PC. Only a minority of patients with PC present with surgically resectable disease, and in the remainder obtaining high quality biopsy material for both diagnosis and molecular testing can prove challenging. Endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is a widely used diagnostic procedure in PC, and allows tumour sampling in patients with both early and late stage disease. This review will provide an update on the role of EUS FNA as a diagnostic tool, as well as a source of genetic material which can be used both for molecular analysis and for the creation of valuable preclinical disease models. We will also consider relevant clinical applications of EUS FNA in the management of PC, and the path towards bringing precision medicine closer to the clinic in this challenging disease.

Original languageEnglish
Article number35
Number of pages15
JournalCancers
Volume10
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • EUS FNA
  • Molecular oncology
  • Pancreatic cancer
  • Precision medicine

Cite this

@article{529b35fa2ad248b7beb00e46c700c9d7,
title = "Reviewing the utility of EUS FNA to advance precision medicine in pancreatic cancer",
abstract = "Advanced pancreatic cancer (PC) is an aggressive malignancy with few effective therapeutic options. While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present no targeted therapies are used in the routine management of PC. Only a minority of patients with PC present with surgically resectable disease, and in the remainder obtaining high quality biopsy material for both diagnosis and molecular testing can prove challenging. Endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is a widely used diagnostic procedure in PC, and allows tumour sampling in patients with both early and late stage disease. This review will provide an update on the role of EUS FNA as a diagnostic tool, as well as a source of genetic material which can be used both for molecular analysis and for the creation of valuable preclinical disease models. We will also consider relevant clinical applications of EUS FNA in the management of PC, and the path towards bringing precision medicine closer to the clinic in this challenging disease.",
keywords = "EUS FNA, Molecular oncology, Pancreatic cancer, Precision medicine",
author = "William Berry and Joanne Lundy and Daniel Croagh and Jenkins, {Brendan J.}",
year = "2018",
month = "2",
day = "1",
doi = "10.3390/cancers10020035",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI",
number = "2",

}

Reviewing the utility of EUS FNA to advance precision medicine in pancreatic cancer. / Berry, William; Lundy, Joanne; Croagh, Daniel; Jenkins, Brendan J.

In: Cancers, Vol. 10, No. 2, 35, 01.02.2018.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Reviewing the utility of EUS FNA to advance precision medicine in pancreatic cancer

AU - Berry, William

AU - Lundy, Joanne

AU - Croagh, Daniel

AU - Jenkins, Brendan J.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Advanced pancreatic cancer (PC) is an aggressive malignancy with few effective therapeutic options. While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present no targeted therapies are used in the routine management of PC. Only a minority of patients with PC present with surgically resectable disease, and in the remainder obtaining high quality biopsy material for both diagnosis and molecular testing can prove challenging. Endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is a widely used diagnostic procedure in PC, and allows tumour sampling in patients with both early and late stage disease. This review will provide an update on the role of EUS FNA as a diagnostic tool, as well as a source of genetic material which can be used both for molecular analysis and for the creation of valuable preclinical disease models. We will also consider relevant clinical applications of EUS FNA in the management of PC, and the path towards bringing precision medicine closer to the clinic in this challenging disease.

AB - Advanced pancreatic cancer (PC) is an aggressive malignancy with few effective therapeutic options. While the evolution of precision medicine in recent decades has changed the treatment landscape in many cancers, at present no targeted therapies are used in the routine management of PC. Only a minority of patients with PC present with surgically resectable disease, and in the remainder obtaining high quality biopsy material for both diagnosis and molecular testing can prove challenging. Endoscopic ultrasound-guided fine needle aspiration (EUS FNA) is a widely used diagnostic procedure in PC, and allows tumour sampling in patients with both early and late stage disease. This review will provide an update on the role of EUS FNA as a diagnostic tool, as well as a source of genetic material which can be used both for molecular analysis and for the creation of valuable preclinical disease models. We will also consider relevant clinical applications of EUS FNA in the management of PC, and the path towards bringing precision medicine closer to the clinic in this challenging disease.

KW - EUS FNA

KW - Molecular oncology

KW - Pancreatic cancer

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85041350785&partnerID=8YFLogxK

U2 - 10.3390/cancers10020035

DO - 10.3390/cancers10020035

M3 - Review Article

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 35

ER -